Back to news

Adaptive Biotechnologies Highlights clonoSEQ’s Central Role in Advancing MRD-Guided Care Across Hematology at ASH 2026

Globe Newswire•18/11/2026•03:00 ET
0

Key Highlights

  • ➤clonoSEQ featured in approximately 100 ASH abstracts, including 27 oral presentations
  • ➤20 biopharma-sponsored clonoSEQ studies include four primary and 11 secondary MRD endpoints
  • ➤PERSEUS and IMMUNOPLANT research examines MRD-guided maintenance de-escalation and consolidation
  • ➤Mount Sinai real-world data identify sustained MRD negativity with survival comparable to general population
  • ➤MAJIC and MIRACLE studies evaluate MRD-guided therapy duration and primary endpoint use in CLL

Expert Statements

Susan Bobulsky, Chief Commercial Officer, MRD, Adaptive Biotechnologies

“The research being presented at ASH underscores clonoSEQ's established position in pivotal clinical trials and showcases its ever-expanding role as a tool to inform patient care strategies across blood cancers”

Susan Bobulsky, Chief Commercial Officer, MRD, Adaptive Biotechnologies

“Multiple myeloma offers a powerful example of this progress, with updated clinical guidelines, a new definition of cure, and important Phase 3 research reinforcing the value of systematic MRD assessment.”

Susan Bobulsky, Chief Commercial Officer, MRD, Adaptive Biotechnologies

“With a strong foundation of clinical evidence, regulatory validation and unparalleled real-world patient experience, Adaptive is helping shape the future of MRD-guided care for blood cancer patients.”

SEATTLE, Nov. 18, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, announced that its next-generation sequencing (NGS)-based clonoSEQ(®) test for measurable residual disease (MRD) assessment will be featured in approximately 100 abstracts, including 27 oral presentations, at the 68(th) Annual Meeting of the American Society of Hematology (ASH), taking place Dec. 12–15, 2026, in New Orleans.

The research at this year’s meeting reflects the continued evolution of MRD assessment across hematologic malignancies, moving beyond measuring the depth of treatment response to informing how therapies are developed, evaluated, and adapted based on individual patient response. Across 20 unique biopharma-sponsored studies featuring clonoSEQ, MRD is utilized as a primary endpoint in four studies and a secondary endpoint in 11, underscoring how highly sensitive MRD assessment has become integral to evaluating therapeutic efficacy and advancing new treatment approaches.

Get started

Create a free account to read the full story.

Sign Up

Already have an account? Log in